| ²é¿´: 239 | »Ø¸´: 2 | |||
| ¡¾½±Àø¡¿ ±¾Ìû±»ÆÀ¼Û2´Î£¬×÷ÕßvoladorÔö¼Ó½ð±Ò 2 ¸ö | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
[×ÊÔ´]
2006±±¾©¹ú¼ÊÒ½Ò©»¯¹¤ÖªÊ¶²úȨ¸ß·åÂÛ̳×ÊÁÏ
|
|||
|
ÎļþĿ¼£º 20060425-PL-1-Wen Xikai.ppt ÎÒ¹ú֪ʶ²úȨ±£»¤Óë¹ú¼Ò֪ʶ²úȨսÂÔ 20060425-PL-2-Zhang Qingkui.ppt ÖйúÒ½Ò©»¯¹¤ÖªÊ¶²úȨ±£»¤ÌåϵÕûÌåÇé¿ö¸ÅÊö 20060425-PL-3-Bai Guangqing.ppt ÖйúҽҩרÀû±£»¤ÖƶȵĽ¨Á¢Óë·¢Õ¹ 20060425-PL-4-Wang Jingchao.ppt ´ÓÖйúµÄרÀûʵ¼ù¿´¶ÔÒ½Ò©»¯¹¤ÉêÇë׫дµÄÒªÇó 20060425-SE01-5-Paul J.Luckern.PPT Understanding Section 337 Proceedings at the U.S. International Trade Commission 20060426-SE02-1-Anthony M.Insogna.PPT PHARMACEUTICAL AND HATCH-WAXMAN LITIGATION 20060426-SE02-2-David Huizenga.ppt Creating Value in Biotechnology 20060426-SE02-3-Darryl H.Steensma.ppt Avoiding Patent Litigation When Exporting A Product To The US 20060426-SE02-5-Raymond Van Dyke.ppt Generic Drug Entry into the United States 20060426-SE02-6-J.Benjiamin Bai.ppt Infringement Analysis and Doctrine of Equivalents 20060426-SE03-1-Esther H.Lim.Esq.ppt Portfolio Management and Pre-Filing Considerations 20060426-SE03-2-Thomas Irving.ppt State of the Law in U.S. Patent Claim Construction 20060426-SE03-4-Jay Z.Zhang.ppt U.S. Pharmaceutical Exclusivity Framework - Hatch-Waxman Act & Others 20060426-SE03-5-Raymond S.Parker.ppt The Supreme Pronouncement on Pharmaceuticals and Patents: The Aftermath of Merck v. Integra 20060426-SE03-6-Steven X.Cui.ppt Innovative Patent Strategies for Antibody Innovations 20060427-SE04-1-Francis Tierney.PPT The Patent Lifecycle of Omeprazole 20060427-SE04-2-Justin Hasford.PPT Lipitor: Big Success, Huge Target 20060427-SE04-3-Matthew Laight.ppt Case Study: Enforcing a Pharmaceutical Process Patent against a Generic Manufacturer in China ÖйúҽҩרÀû±£»¤ÖƶȵĽ¨Á¢Óë·¢Õ¹£°×¹âÇå.ppt Patent Procurement and Enforcement in China£Áú´«ºì.ppt ÏÂÔØµØÖ·£ºhttp://roadman.ys168.com/ [ Last edited by volador on 2008-9-26 at 17:23 ] |
» ²ÂÄãϲ»¶
²©µ¼ÍƼö
ÒѾÓÐ2È˻ظ´
ÄÄÀï×ö¸Ê°±ËáÊÜÌåÓëÅäÌå½áºÏÂʵÄÊÔÑé
ÒѾÓÐ0È˻ظ´
Ò©ÀíѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ235È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§ºÍÉúÎïѧµÈרҵµÄÑо¿Éú
ÒѾÓÐ7È˻ظ´
[ѧϰ×ÊÁÏ·ÖÏí] FAERSÊý¾Ý¿âµÄ²»Á¼·´Ó¦ÍÚ¾ò(ƵÊý·¨/±´Ò¶Ë¹·¨)
ÒѾÓÐ1È˻ظ´
ÕÐÊÕҽѧ¡¢»ù´¡Ò½Ñ§Ààµ÷¼ÁÑо¿Éú
ÒѾÓÐ0È˻ظ´
ÊÇ·ñÊôÓÚÆ¢ÉöÑôÐéÖ¤
ÒѾÓÐ0È˻ظ´
¹ØÓÚSCIÔÓÖ¾·¢±í¹ÒÃû
ÒѾÓÐ32È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§Ôº×ÔÉíÃâÒß²¡¿ÎÌâ×éÕÐÊÕ»ù´¡Ò½Ñ§Ïà¹Ø×¨ÒµµÄµ÷¼ÁÑо¿Éú
ÒѾÓÐ2È˻ظ´
¹ãÎ÷Ò½¿Æ´óѧ»ù´¡Ò½Ñ§ÔºÕÐÊÕ»ù´¡Ò½Ñ§¡¢Ò©Ñ§¡¢ÉúÎï¼ìÑéÏà¹Ø×¨ÒµµÄÑо¿Éú
ÒѾÓÐ1È˻ظ´
Õâ¸ö×Ô·¢¼ÓÑõ·´Ó¦µÄ»úÀíÊÇʲô£¿
ÒѾÓÐ7È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
¼òµ¥»Ø¸´
msd2phd2Â¥
2008-09-27 23:54
»Ø¸´















»Ø¸´´ËÂ¥
ͶƱ: